Navigation Links
Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock
Date:5/29/2012

TI may not use the net proceeds of the Offering as expected as well as risks related to developments in the biopharmaceutical industry, the outcome of preclinicial and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, costs of developing, producing and selling CTI's drug candidates, that CTI's acquisition of certain assets from S*BIO Pte Ltd. may not be timely completed, if at all, that the projected benefits of such acquisition may not materialize as expected, that CTI may not be able to successfully implement its plans, strategies and objectives related to such acquisition and development of the acquired compounds, the risk that CTI may not be able to sustain its current cost controls, and the risk that CTI may not be able to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling its drug candidates. Further risks and uncertainties include CTI's operating expenses continue to exceed its net revenues, that CTI may not be able to further reduce its operating expenses, that CTI will continue to need to raise capital to fund its operating expenses and may not be able to raise sufficient amounts to fund its continued operation as well as other risks listed or described from time to time in CTI's most recent filings with the Securities and Exchange Commission on Forms 10-K, 10-Q and 8-K. Except as required by law, CTI does not intend to update any of the statements in this press release upon further developments.

Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: media@ctiseattle.com
www.CellTherapeutics.com/press_room  

Investors Contact:
Ed Bell
T: 206.272.4345

Lindsey Jesch Logan
T: 206.272.4347
F: 206.272.4434
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
2. Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019
3. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
4. Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy
5. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
6. Regulus Therapeutics Appoints Bruce Carter to its Board of Directors
7. Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones
8. Echo Therapeutics to Present Positive Clinical Trial Results at the 72nd Scientific Sessions of the American Diabetes Association
9. Islet Sciences Announces DiaKine Therapeutics Novel Diabetes, Atherosclerosis Drugs Receives European Patent Protection
10. Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin
11. Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... 2015  MiMedx Group, Inc. (NASDAQ: MDXG ), ... and patent-protected processes to develop and market advanced products ... Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced ... has been awarded the Lifetime Achievement Award in the ... The Entrepreneur Of The Year Program, now ...
(Date:6/29/2015)... ... June 29, 2015 , ... The StampedeCon ... and for the fourth year in a row, will bring top technology professionals to ... place at the intersection of data and technology. The event is proudly sponsored by ...
(Date:6/29/2015)... Elsevier , a world-leading provider of ... announced the highlights of its journal Impact Factor performance ... (JCR) published by Thomson Reuters, Elsevier saw 55% of ... ahead of the aggregate across other journals. In 2014, ... categories, up from 61 in 2013. An ...
(Date:6/26/2015)... 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or "the ... all nominees listed in the management information circular ... 2015 Annual Meeting of Shareholders, held earlier today, ... the following 5 nominees proposed by management were ... until the Company,s next Annual Meeting of Shareholders ...
Breaking Biology Technology:EY Entrepreneur Of The Year Program Recognizes Pete Petit, The Chairman & CEO of MiMedx 2StampedeCon Announces 2015 Agenda 2StampedeCon Announces 2015 Agenda 3Elsevier Announces 2014 Citation Impact Highlights 2Elsevier Announces 2014 Citation Impact Highlights 3iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 2iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 3
... Multiporator / Electroporator 2510 , , , , , , , ... Protocol No. 4308 915.521 02/2002 , , , ... , Microorganism , ... Cell type , Bacteria, gram positive, , ...
... , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.514 04/2002 , ... , , , , ... , Cell type , Bacteria, ...
... , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.511 04/2002 , ... , , , , ... , Cell type , Bacteria, gram ...
Cached Biology Technology:Mycobacterium intracellulare 2Escherichia coli K12 2Escherichia coli K12 3Escherichia coli C600 2Escherichia coli C600 3
(Date:6/23/2015)... GARDENS, Fla. , June 23, 2015 ... identity management and authentication solutions, today announced enhanced ... strong, multi-factor authentication solution.  The enhancements build ... use of the DigitalPersona Altus platform and ... reader compatibility. In today,s environment ...
(Date:6/17/2015)... GERMANTOWN, Maryland , June 17, 2015 ...   Produktlinie mit DNA-Tests verbessert den Analyseprozess und ... QGEN ; Frankfurt Prime Standard: QIA) hat heute in ... Produktlinie Investigator ® für ... Die neuen Kits zur Erstellung genetischer Fingerabdrücke bieten eine ...
(Date:6/17/2015)... , June 17, 2015  Crossmatch™, a leading ... that its U.are.U ® 4500 fingerprint readers ... Eateries, Inc., a San Jose, ... to increase security, improve accountability and reduce fraud ... instant, non-repudiable identity confirmation for employee sign in ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3
... ARBOR, Mich. An early laboratory success is taking ... gland transplants that could one day prevent a currently ... The scientists were able to induce embryonic stem ... hormone essential to maintaining bone density. The laboratory results ...
... ANN ARBOR, Mich.---Brain implants that can more clearly record ... at the University of Michigan. The findings could eventually ... as Parkinson,s disease and paralysis. Neural electrodes must ... When the electrodes are implanted, the brain first reacts ...
... calling on Congress to support the Consistency, Accuracy, Responsibility ... (CARE bill), which would ensure that states set minimum ... bill (H.R. 3652) was introduced Sept. 28 in the ... "The introduction of the CARE bill ...
Cached Biology News:Stem cell success points to way to regenerate parathyroid glands 2A step toward better brain implants using conducting polymer nanotubes 2A step toward better brain implants using conducting polymer nanotubes 3SNM urges Congress to support CARE bill 2
Mouse monoclonal antibody raised against a partial recombinant STAU2. NCBI Entrez Gene ID = STAU2...
...
Mouse polyclonal antibody to NR2F2 - nuclear receptor subfamily 2, group F, member 2...
... Pack provides optimized blocking and wash ... Clarifier: Ready-to-use wash solutions have been ... Coated Slides for Microarrays (Product Code ... Buffer: 1L • Microarray Post Hybridization ...
Biology Products: